Literature DB >> 11323221

Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus.

Y Futei1, M Amagai, K Ishii, K Kuroda-Kinoshita, K Ohya, T Nishikawa.   

Abstract

Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are autoimmune skin diseases caused by autoantibodies against desmoglein (Dsg) 3 and Dsg1. We have previously developed ELISAs using recombinant Dsg3 and Dsg1 expressed by baculovirus as a diagnostic tool for pemphigus. In this study, we determined the frequency of coexistence of IgA class as well as distribution of IgG subclass. Two out of 49 PV and PF sera tested had anti-Dsg1 IgA in addition to anti-Dsg1 IgG. Interestingly, one of them showed prominent pustular formation. Among IgG subclass, IgG4 was predominant and found in all of the 30 PV and 19 PF sera tested, followed by IgG1, detected in 25 out of 30 PV and 12 out of 19 PF sera. Even though IgG2 and IgG3 were detected in 13 and one PV and 6 and 4 PF sera, respectively, the ELISA titers had barely exceeded the cutoff value in most of the cases. There was no IgG subclass shift during the course of the disease in seven cases examined. These findings indicate that IgG4 subclass is the predominant autoantibodies in both PV and PF, while IgG1 is also frequently found.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323221     DOI: 10.1016/s0923-1811(00)00158-4

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  37 in total

1.  Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.

Authors:  N Sami; K C Bhol; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab.

Authors:  Alice Cho; Bridget Bradley; Robert Kauffman; Lalita Priyamvada; Yevgeniy Kovalenkov; Ron Feldman; Jens Wrammert
Journal:  JCI Insight       Date:  2017-06-15

Review 3.  Diagnosis and clinical features of pemphigus foliaceus.

Authors:  Kirk A James; Donna A Culton; Luis A Diaz
Journal:  Dermatol Clin       Date:  2011-07       Impact factor: 3.478

Review 4.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

5.  Enrichment of total serum IgG4 in patients with pemphigus.

Authors:  T Funakoshi; L Lunardon; C T Ellebrecht; A R Nagler; C E O'Leary; A S Payne
Journal:  Br J Dermatol       Date:  2012-09-27       Impact factor: 9.302

Review 6.  Setting the target for pemphigus vulgaris therapy.

Authors:  Christoph T Ellebrecht; Aimee S Payne
Journal:  JCI Insight       Date:  2017-03-09

7.  Divergent Specificity Development of IgG1 and IgG4 Autoantibodies in Endemic Pemphigus Foliaceus (Fogo Selvagem).

Authors:  Mike Maldonado; Luis A Diaz; Phillip Prisayanh; Jinsheng Yang; Bahjat F Qaqish; Valeria Aoki; Gunter Hans-Filho; Evandro A Rivitti; Donna A Culton; Ye Qian
Journal:  Immunohorizons       Date:  2017-08-01

8.  Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus.

Authors:  Amina Toumi; Marwah Adly Saleh; Jun Yamagami; Olfa Abida; Maryem Kallel; Abderrahmen Masmoudi; Sondes Makni; Hamida Turki; Takahisa Hachiya; Keiko Kuroda; John R Stanley; Hatem Masmoudi; Masayuki Amagai
Journal:  J Dermatol Sci       Date:  2013-02-19       Impact factor: 4.563

9.  Chronic sclerosing sialadenitis of the submandibular gland: an entity of IgG4-related sclerosing disease.

Authors:  Tzu-Wei Wei; Ching-Feng Lien; Tun-Yen Hsu; Hong-Lin He
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 10.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.